Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Selected demographic and clinical characteristics of breast cancer patients included in the Shanghai Breast Cancer Survival Study.

From: Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study

Variables Levels Number of cases % 5-year survival rate P
Age at diagnosis <40 126 4.51 0.9029 <0.01
  40-49 1128 40.42 0.9166  
  50-59 794 28.45 0.8827  
  60-69 469 16.8 0.8586  
  ≥70 274 9.82 0.8356  
Education <Middle School 361 12.93 0.7941 <0.01
  Middle School 988 35.40 0.8948  
  > Middle School 1442 51.67 0.9096  
Income <1,000 1723 61.73 0.8696 <0.01
(CNY¥/person/month) 1,000 - 1,999 777 27.84 0.9141  
  ≥2,000 291 10.43 0.9415  
TNM stage 0 63 2.26 1.0000 <0.01
  I 871 31.21 0.9545  
  IIa 945 33.86 0.9221  
  IIb 549 19.67 0.8174  
  III-IV 272 9.75 0.6724  
Histologic grade I 438 15.69 0.9611 <0.01
  II 1312 47.01 0.9002  
  III 803 28.77 0.8274  
  Unknown 238 8.53 0.9231  
Histologic type* Noninvasive (DCIS, LCIS) 96 3.44 1.0000 <0.01
  ILC NOS 215 7.70 0.8797  
  IDC NOS 1924 68.94 0.8745  
  Special types 527 18.88 0.9264  
  Unknown 29 1.04 0.8966  
ERα Positive (> = 10%) 1740 62.34 0.9206 <0.01
  Negative 1051 37.66 0.8354  
PR Positive (> = 1%) 1632 58.47 0.9183 <0.01
  Negative 1159 41.53 0.8465  
HER2 Positive (3+) 849 30.42 0.8621 0.02
  Borderline (2+) 227 8.13 0.8768  
  Negative (0-1+) 1715 61.45 0.9032  
Molecular subtype** Luminal A 1355 48.55 0.9286 <0.01
  Luminal B 467 16.73 0.8862  
  HER2 382 13.69 0.8322  
  Triple negative 360 12.90 0.8069  
  HER2 borderline 227 8.13 0.8768  
Radiotherapy Yes 874 31.31 0.8409 <0.01
  No 1917 68.69 0.9098  
Chemotherapy Yes 2558 91.65 0.8890 0.99
  No 233 8.35 0.8818  
Immunotherapy Yes 477 17.09 0.9118 0.18
  No 2310 82.77 0.8844  
  Unknown 4 0.14 0.7500  
Tamoxifen *** Yes 1484 53.17 0.9123 <0.01
  No 1306 46.79 0.8612  
  1. *DCIS: ductal carcinoma in situ; LCIS: lobular carcinoma in situ; IDC NOS: invasive ductal carcinoma not otherwise specified; ILC NOS: invasive lobular carcinoma not otherwise specified; Special types: including mucinous, papillary, medullary, tubular, cribriform, metaplastic, mixed, and other rare invasive cancers.
  2. ** Luminal A: ERα+ and/or PR+, HER2-; luminal B: ERα+ and/or PR+, HER2+; HER2: HER2+, ERα-, and PR-; triple negative: ERα-, PR-, HER2-: HER2 borderline: weak staining of HER2 (2+).
  3. ***One case with unknown tamoxifen use was excluded.